Depression und Schlafstörungen - Neuer Wirkansatz in der Therapie der Major Depression

Literatur

• 01 Guilleminault C . Efficacy of the new antidepressant agomelatine versus venlafaxine on subjective sleep of patients with Major Depressive Disorder.  Eur Neuropsychopharm Vol. 2006;  15 Suppl 3 S419
• 02 Millan MJ . et al . The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.  J Pharmacol Exp Ther . 2003;  306 (3) 954-964
• 03 Olie JP . Kasper S . Efficacy of agomelatine, a MT₁/MT₂ receptor agonist with 5-HT_2C antagonistic properties, in major depressive disorder.  Int J Neuropsychopharmacol. 2007;  10 (5) 661-673
• 04 Quera Salva MA . et al . Major depressive disorder, sleep EEG and agomelatine: an open-label study.  Int J Neuropsychopharmacol. 2007;  10 (5) 691-696